Table. Summary of Major Sentinel Lymph Node (SLN) Trials.

Trial	SLN Status	Comparison		No. of Patients Evaluated
NSABP B-327	Negative	SLNB alone versus SLNB + ALND in T1 to T2, cN0 patients undergoing mastectomy or BCS		SLNB alone, n = 2011 SLNB + ALND, n = 1975
IBCSG 23-0167	Positive 1 or more micrometastases	SLNB alone versus SLNB + ALND in T1 to T2 patients undergoing mastectomy or BCS		SLNB alone, n = 467 SLNB + ALND, n = 464
ACOSOG Z001113,14	Positive 1 or 2 positive SLNs	SLNB alone versus SLNB + ALND in T1 to T2, cN0 patients undergoing BCS and whole-breast RT		SLNB alone, n = 436 SLNB + ALND, n = 420
AMAROS76	Positive 1 or 2 positive SLNs	ALND versus axillary RT in T1 to T2, cN0 patients treated with BCS or mastectomy		ALND, n = 744 Axillary RT, n = 681
Extended
Follow-up	Metastatic Non-SLNs in ALND, %	Axillary Recurrence, %	Overall Survival, %	Disease-Free Survival, %
95.6 mo (mean)		SLNB alone, 0.7 SLNB + ALND, 0.4 (P = .22)	SLNB alone, 90.3a SLNB + ALND, 91.8a (P = .12)	SLNB alone, 81.5a SLNB + ALND, 82.4a (P = .54)
5 y (median)	13	SLNB alone, 0.86 SLNB + ALND, 0.22	SLNB alone, 97.5 SLNB + ALND, 97.6 (P = .73)	SLNB alone, 87.8 SLNB + ALND, 84.4 (P = .16)
6.3 y (median)	27	SLNB alone, 0.9 SLNB + ALND, 0.5 (P = .45)	SLNB alone, 91.8 SLNB + ALND, 92.5 (P = .25)	SLNB alone, 83.8 SLNB + ALND, 82.2 (P = .14)
6.1 y (median)	33	ALND, 0.43 Axillary RT, 1.19	ALND, 93.3 Axillary RT, 92.5 (P = .34)	ALND, 86.9 Axillary RT, 82.7 (P = .18)

Abbreviations: ACOSOG, American College of Surgeons Oncology Group; ALND, axillary lymph node dissection; AMAROS, After Mapping of the Axilla: Radiotherapy or Surgery?; BCS, breast-conserving surgery; cN0, clinically node negative; IBCSG, International Breast Carcinoma Study Group; NSABP, National Surgical Adjuvant Breast and Bowel Project; RT, radiotherapy; SLNB, sentinel lymph node biopsy.

^a8-year Kaplan-Meier estimates.